BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2021 on Thursday, February 10, 2022, before the U.S. financial markets open.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022.

Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826(“pyrilutamide”) in China for the treatment of acne vulgaris.

Senzime has selected Mercury Medical as their exclusive United States provider of Biomedical repair and maintenance services for their TetraGraph product line.

Nanalysis Scientific Corp. is pleased to announce it has been named to the 2022 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.

Perineologic, a subsidiary of Corbin Clinical Resources, Inc., announced the appointment of Jim Fortune as president, who in this role will be responsible for the company’s business strategy and operations management.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today lauded the second high impact study this month solidifying EBV as the primary driver of the development of MS.

Mammoth Biosciences, Inc. , today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its DETECTR BOOST ® SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.

The global Healthcare Chatbots Market is forecasted to be worth USD 594.8 Million by 2027, according to a current analysis by Emergen Research.

Simavita Limited (“ Simavita ” or the “ Company ”) announces that it has ceased to be a reporting issuer, effective January 21, 2022 (the “ Commencement Date ”) pursuant to an order of the British Columbia Securities Commission dated January 21, 2022 (the “ BCSC Order ”).